Annual Total Long Term Liabilities
$5.33 M
-$2.59 M-32.70%
31 December 2023
Summary:
Celldex Therapeutics annual total long term liabilities is currently $5.33 million, with the most recent change of -$2.59 million (-32.70%) on 31 December 2023. During the last 3 years, it has fallen by -$6.94 million (-56.57%). CLDX annual total long term liabilities is now -93.55% below its all-time high of $82.70 million, reached on 31 December 2016.CLDX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$5.18 M
+$912.00 K+21.36%
01 September 2024
Summary:
Celldex Therapeutics quarterly total long term liabilities is currently $5.18 million, with the most recent change of +$912.00 thousand (+21.36%) on 01 September 2024. Over the past year, it has dropped by -$521.00 thousand (-9.14%). CLDX quarterly long term liabilities is now -93.96% below its all-time high of $85.83 million, reached on 30 June 2017.CLDX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -32.7% | -9.1% |
| 3 y3 years | -56.6% | -44.4% |
| 5 y5 years | -72.2% | -72.1% |
CLDX Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -56.6% | at low | -54.5% | +31.4% |
| 5 y | 5 years | -72.2% | at low | -72.1% | +31.4% |
| alltime | all time | -93.5% | -94.0% | +5281.0% |
Celldex Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $5.18 M(+21.4%) |
| June 2024 | - | $4.27 M(+8.3%) |
| Mar 2024 | - | $3.94 M(-26.0%) |
| Dec 2023 | $5.33 M(-32.7%) | $5.33 M(-6.5%) |
| Sept 2023 | - | $5.70 M(-7.0%) |
| June 2023 | - | $6.13 M(-6.6%) |
| Mar 2023 | - | $6.56 M(-17.2%) |
| Dec 2022 | $7.92 M(-8.4%) | $7.92 M(+5.3%) |
| Sept 2022 | - | $7.52 M(-5.0%) |
| June 2022 | - | $7.92 M(-30.4%) |
| Mar 2022 | - | $11.38 M(+31.6%) |
| Dec 2021 | $8.65 M(-29.5%) | $8.65 M(-7.1%) |
| Sept 2021 | - | $9.31 M(+19.7%) |
| June 2021 | - | $7.78 M(-1.8%) |
| Mar 2021 | - | $7.92 M(-35.5%) |
| Dec 2020 | $12.28 M(-28.9%) | $12.28 M(-9.7%) |
| Sept 2020 | - | $13.60 M(+12.2%) |
| June 2020 | - | $12.12 M(-32.2%) |
| Mar 2020 | - | $17.87 M(+3.5%) |
| Dec 2019 | $17.26 M(-9.8%) | $17.26 M(-7.0%) |
| Sept 2019 | - | $18.57 M(-12.0%) |
| June 2019 | - | $21.11 M(-7.8%) |
| Mar 2019 | - | $22.89 M(+19.6%) |
| Dec 2018 | $19.15 M(-62.8%) | $19.15 M(-17.8%) |
| Sept 2018 | - | $23.30 M(-23.2%) |
| June 2018 | - | $30.35 M(-8.8%) |
| Mar 2018 | - | $33.28 M(-35.4%) |
| Dec 2017 | $51.52 M(-37.7%) | $51.52 M(-31.6%) |
| Sept 2017 | - | $75.35 M(-12.2%) |
| June 2017 | - | $85.83 M(+0.7%) |
| Mar 2017 | - | $85.19 M(+3.0%) |
| Dec 2016 | $82.70 M(+379.7%) | $82.70 M(+409.7%) |
| Sept 2016 | - | $16.23 M(-1.6%) |
| June 2016 | - | $16.49 M(-0.6%) |
| Mar 2016 | - | $16.59 M(-3.8%) |
| Dec 2015 | $17.24 M(+45.3%) | $17.24 M(+66.2%) |
| Sept 2015 | - | $10.37 M(-2.6%) |
| June 2015 | - | $10.65 M(-3.2%) |
| Mar 2015 | - | $11.00 M(-7.3%) |
| Dec 2014 | $11.86 M(+70.7%) | $11.86 M(+11.1%) |
| Sept 2014 | - | $10.68 M(-3.6%) |
| June 2014 | - | $11.07 M(+50.8%) |
| Mar 2014 | - | $7.35 M(+5.7%) |
| Dec 2013 | $6.95 M(-42.5%) | $6.95 M(-6.3%) |
| Sept 2013 | - | $7.42 M(+11.7%) |
| June 2013 | - | $6.64 M(-40.2%) |
| Mar 2013 | - | $11.09 M(-8.2%) |
| Dec 2012 | $12.08 M(-19.3%) | $12.08 M(-11.8%) |
| Sept 2012 | - | $13.69 M(-8.7%) |
| June 2012 | - | $15.00 M(-8.0%) |
| Mar 2012 | - | $16.31 M(+8.9%) |
| Dec 2011 | $14.97 M(+3.4%) | $14.97 M(-11.9%) |
| Sept 2011 | - | $17.00 M(+5.8%) |
| June 2011 | - | $16.06 M(-9.2%) |
| Mar 2011 | - | $17.70 M(+22.2%) |
| Dec 2010 | $14.48 M(-72.3%) | $14.48 M(-60.3%) |
| Sept 2010 | - | $36.51 M(-3.6%) |
| June 2010 | - | $37.85 M(-3.3%) |
| Mar 2010 | - | $39.16 M(-25.0%) |
| Dec 2009 | $52.19 M(+39.0%) | $52.19 M(+44.0%) |
| Sept 2009 | - | $36.23 M(-2.7%) |
| June 2009 | - | $37.25 M(-1.0%) |
| Mar 2009 | - | $37.64 M(+0.2%) |
| Dec 2008 | $37.56 M | $37.56 M(+1.7%) |
| Sept 2008 | - | $36.92 M(+0.5%) |
| June 2008 | - | $36.75 M(+3063.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2008 | - | $1.16 M(+214.0%) |
| Dec 2007 | $370.00 K(-99.2%) | $370.00 K(-99.2%) |
| Sept 2007 | - | $48.59 M(-2.0%) |
| June 2007 | - | $49.58 M(+4.4%) |
| Mar 2007 | - | $47.50 M(-3.5%) |
| Dec 2006 | $49.23 M(+314.8%) | $49.23 M(+2.3%) |
| Sept 2006 | - | $48.12 M(-2.1%) |
| June 2006 | - | $49.15 M(+1.1%) |
| Mar 2006 | - | $48.61 M(+309.5%) |
| Dec 2005 | $11.87 M(+464.2%) | $11.87 M(+0.7%) |
| Sept 2005 | - | $11.79 M(-0.5%) |
| June 2005 | - | $11.85 M(+519.2%) |
| Mar 2005 | - | $1.91 M(-9.0%) |
| Dec 2004 | $2.10 M(+361.1%) | $2.10 M(+513.9%) |
| Sept 2004 | - | $342.70 K(+313.4%) |
| Sept 2003 | - | $82.90 K(-60.0%) |
| June 2003 | - | $207.40 K(-37.5%) |
| Mar 2003 | - | $331.80 K(-27.3%) |
| Dec 2002 | $456.20 K(-83.1%) | $456.20 K(+196.2%) |
| Sept 2002 | - | $154.00 K(-92.0%) |
| June 2002 | - | $1.92 M(-16.7%) |
| Mar 2002 | - | $2.31 M(-14.3%) |
| Dec 2001 | $2.69 M(-36.4%) | $2.69 M(-12.5%) |
| Sept 2001 | - | $3.08 M(-11.1%) |
| June 2001 | - | $3.46 M(-10.0%) |
| Mar 2001 | - | $3.85 M(-9.1%) |
| Dec 2000 | $4.23 M(+1472.4%) | $4.23 M(+59.1%) |
| Sept 2000 | - | $2.66 M(-7.9%) |
| June 2000 | - | $2.89 M(-7.4%) |
| Mar 2000 | - | $3.12 M(+1058.6%) |
| Dec 1999 | $269.20 K(-51.1%) | $269.20 K(-32.7%) |
| Sept 1999 | - | $400.00 K(0.0%) |
| June 1999 | - | $400.00 K(-33.3%) |
| Mar 1999 | - | $600.00 K(+9.1%) |
| Dec 1998 | $550.10 K(-21.4%) | $550.10 K(-54.2%) |
| Sept 1998 | - | $1.20 M(+50.0%) |
| June 1998 | - | $800.00 K(0.0%) |
| Mar 1998 | - | $800.00 K(+14.3%) |
| Dec 1997 | $700.00 K(+600.0%) | $700.00 K(-53.3%) |
| Sept 1997 | - | $1.50 M(-1600.0%) |
| Mar 1997 | - | -$100.00 K(-150.0%) |
| Sept 1996 | - | $200.00 K(+100.0%) |
| June 1996 | - | $100.00 K(0.0%) |
| Mar 1996 | - | $100.00 K(0.0%) |
| Dec 1995 | $100.00 K(-80.0%) | $100.00 K(-50.0%) |
| Sept 1995 | - | $200.00 K(0.0%) |
| June 1995 | - | $200.00 K(-50.0%) |
| Mar 1995 | - | $400.00 K(-20.0%) |
| Dec 1994 | $500.00 K(-16.7%) | $500.00 K(0.0%) |
| Sept 1994 | - | $500.00 K(+25.0%) |
| June 1994 | - | $400.00 K(-20.0%) |
| Mar 1994 | - | $500.00 K(-16.7%) |
| Dec 1993 | $600.00 K(>+9900.0%) | $600.00 K(>+9900.0%) |
| Mar 1993 | - | $0.00(0.0%) |
| Dec 1992 | $0.00(0.0%) | - |
| Oct 1992 | - | $0.00(0.0%) |
| July 1992 | - | $0.00(0.0%) |
| Apr 1992 | - | $0.00(0.0%) |
| Apr 1992 | $0.00(-100.0%) | - |
| Jan 1992 | - | $0.00(-100.0%) |
| Oct 1991 | - | $100.00 K(>+9900.0%) |
| July 1991 | - | $0.00(-100.0%) |
| Apr 1989 | $2.30 M(-4.2%) | $2.30 M(-4.2%) |
| Apr 1988 | $2.40 M(-4.0%) | $2.40 M(-4.0%) |
| Apr 1987 | $2.50 M(-51.9%) | $2.50 M(-51.9%) |
| Apr 1986 | $5.20 M | $5.20 M |
FAQ
- What is Celldex Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Celldex Therapeutics?
- What is Celldex Therapeutics annual total long term liabilities year-on-year change?
- What is Celldex Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly long term liabilities year-on-year change?
What is Celldex Therapeutics annual total long term liabilities?
The current annual total long term liabilities of CLDX is $5.33 M
What is the all time high annual total long term liabilities for Celldex Therapeutics?
Celldex Therapeutics all-time high annual total long term liabilities is $82.70 M
What is Celldex Therapeutics annual total long term liabilities year-on-year change?
Over the past year, CLDX annual total long term liabilities has changed by -$2.59 M (-32.70%)
What is Celldex Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of CLDX is $5.18 M
What is the all time high quarterly long term liabilities for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly total long term liabilities is $85.83 M
What is Celldex Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, CLDX quarterly total long term liabilities has changed by -$521.00 K (-9.14%)